SCHEMBL20043315

SCHEMBL20043315

CN1CC(=O)OB(c2cncc(N3CCCC3)n2)OC(=O)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 5/20 0.33
HRH4 Q9H3N8 3/20 0.33
CYP11B1 P15538 3/20 0.33
CYP11B2 P19099 3/20 0.33
PIM1 P11309 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2A1 P68400 1/20 0.33
PDE10A Q9Y233 3/20 0.32
FFAR4 Q5NUL3 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
HTR1A P08908 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20043318 0.79 CYP3A4 (0.31) CYP3A4CYP2C9CYP2C19
SCHEMBL20043393 0.77
SCHEMBL20043310 0.75 BACE1 (0.31)
SCHEMBL20043392 0.75
SCHEMBL31015657 0.74 PDE10A (0.34) PIM2HRH4CYP11B1CYP11B2PDE10A
SCHEMBL20043319 0.72
SCHEMBL20043309 0.71 MITF (0.34)
SCHEMBL10137347 0.69 HRH4 (0.39) PIM2HRH4CYP11B1CYP11B2KDM4E
SCHEMBL15314157 0.64 HTR3E (0.38) CYP3A4CYP2C9CYP2C19
SCHEMBL15314170 0.64 CYP3A4 (0.35) CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261200-B2 Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2022-03-01 US disclosed
US-20190276478-A1 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC 2019-09-12 US disclosed
US-20190276478-A1 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC 2019-09-12 US disclosed
WO-2018067762-A2 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11261200-B2 Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections FNTB, CYP2F1, SDHB PIM2 1555/4885HRH4 1815/4885CYP11B1 55/4885
US-20190276478-A1 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS FNTB, CYP2F1, SDHB PIM2 1555/4885HRH4 1815/4885CYP11B1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.